ESPERION THERAPEUTICS

2,5700

25-ноября-24 15:45:01

15 мин. задержка

Акции

+0,0500

+1,98%

Сегодняшний диапазон

2,5150 - 2,6150

ISIN

N/A

Источник

NASDAQ

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

21 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

18 ноя 2024 09:30:00 Источник Nasdaq GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

08 ноя 2024 15:15:00 Источник Nasdaq GlobeNewswire
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

07 ноя 2024 05:00:00 Источник Nasdaq GlobeNewswire
Esperion to Participate in Upcoming Jefferies London Healthcare Conference

04 ноя 2024 07:00:25 Источник Nasdaq GlobeNewswire
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

31 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion to Report Third Quarter 2024 Financial Results on November 7

24 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

02 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

25 сен 2024 15:30:00 Источник Nasdaq GlobeNewswire
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

05 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

03 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

26 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

12 авг 2024 05:00:00 Источник Nasdaq GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

07 авг 2024 15:30:00 Источник Nasdaq GlobeNewswire
Esperion to Report Second Quarter 2024 Financial Results on August 12

25 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion to Participate in Upcoming BTIG Biotech Conference

24 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

16 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

28 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire
Esperion to Participate in Upcoming June Investor Conferences

23 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

22 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.